United Immunity, Co., Ltd., a biotech company developing pullulan-based Myeloid Targeting Platform™, with its partners from the University of Tokyo, Kyoto University, Nagasaki University and Aichi Cancer Center announced today the publication of preclinical data demonstrating that pullulan nanoparticle (PNP, shown as PNG in the article) actively delivers the spike (S) protein of SARS-CoV-2 to antigen-presenting medullary macrophages through the selective binding to the C-type lectin receptor SIGN-R1 (mouse equivalent of human DC-SIGN).
See further information on the press release.
（Press Release_2024.10.01_ENG）